abstract |
The present invention is capable of directing immune cells, e.g., T lymphocytes, to a target antigen when the antigen binds to a polypeptide comprising a transmembrane domain derived from a T cell co-inhibitory protein, e.g., CTLA4 or PD-1, and T cells to a therapeutic polypeptide, such as a chimeric antigen receptor, capable of causing a cell to proliferate or kill an antigen-displaying cell. The present invention also relates to T lymphocytes expressing said polypeptides and to the use of such T lymphocytes for treating diseases such as cancer. |